This post is presented by our media partner Psychedelic News Wire
View the original article here.
Psychedelics like LSD, psilocybin, ayahuasca, and MDMA have demonstrated potential in managing conditions like addiction, post-traumatic stress disorder, and depression. These drugs can give rise to profound experiences that, when paired with talk therapy, may bring about substantial therapeutic benefits.
This has grown the popularity of psychedelic-assisted therapy as more and more studies tout the benefits of this approach, particularly for patients with mental health conditions who’ve gained no benefit from traditional treatments.
Now new research by investigators at the University Medical Center Gröningen and the Champalimaud Foundation calls to attention gaps in how the psycho-therapeutic aspect of these therapies is described, possibly impeding their safety and effectiveness. For their research, the investigators systematically reviewed forty-five studies which involved more than 1400 participants to evaluate how well the psychological interventions were reported.
They found that psychological interventions varied extensively across studies and were poorly reported in most cases, with many lacking detailed data about the qualifications of therapists involved, specific methods used, and the therapy model setting. Important details like the number of therapy sessions, which is crucial for determining the amount of therapy required for effective treatment, was often disregarded.
While the quality of the therapist-patient relationship is known to influence the effectiveness of psychotherapy, other factors also play a crucial role in patient outcomes.
Carolina Seybert, the first author of the study, explained that measuring how closely therapists followed treatment protocols was necessary for ensuring effectiveness and safety. However, most studies didn’t track adherence as it was both time-consuming and costly, which made it hard for investigators to determine whether therapy was delivered as intended.
The investigators also found that unlike ayahuasca and psilocybin studies, MDMA research had higher reporting quality because they used one standardized manual for treatment.
In their report, the investigators explained that having clear guidelines could enhance how interventions were reported, noting that this would help other researchers to better understand which psychological interventions were most effective for certain mental conditions while also enabling them to deliver psychedelic-assisted psychotherapy in a way that enhanced its applicability in practical settings.
Seybert added that improving reporting standards would better guide professional boards and clinicians on the competencies, training, and experience required to deliver these treatments effectively and safely.
One of the study’s senior authors, Albert Oliveira-Maia, then noted that since reporting was already improving, regulatory authorities would have access to more data required to make informed decisions. The investigators’ findings were reported in the Lancet journal.
Entities like Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) need to analyze these research finding closely and see whether any of the recommendations made can help them during their own psychedelic medicine development.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
This post was originally published by our media partner here.